CD96 Double Nickase Plasmid (h): sc-407300-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD96 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD96 Double Nickase Plasmid (h) and CD96 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD96. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD96 Antibody (NK92.50.1): sc-53574
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD96 Double Nickase Plasmid (h) | sc-407300-NIC | 20 µg | $410.00 |
CD96 encodes a type I transmembrane immunoglobulin superfamily receptor expressed on subsets of T cells and NK cells, where it modulates immune synapse formation and effector function through interactions with nectin/nectin-like ligands such as CD155 (PVR) and CD111 (NECTIN1). By integrating signals within adhesion and co-inhibitory/co-stimulatory networks, CD96 influences cytotoxicity, cytokine production, and lymphocyte activation thresholds in the tumor microenvironment. Altered CD96 activity has been linked to immune evasion and changes in antitumor immunity, and it is frequently studied alongside checkpoint pathways including TIGIT and CD226 that compete for shared ligands. These features make CD96 a useful target for dissecting immune regulatory circuits relevant to cancer immunology and inflammatory disease research.
CD96 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD96 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD96. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD96 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD96-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.